The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Sickle Cell Disease Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCAT 2024 | Is there potential for the use of combination therapies in sickle cell disease?
In this video, Sanne Lugthart, MD, PhD, University Hospitals of Bristol and Weston NHS Foundation Trust, Bristol, UK, briefly discusses the potential of combination therapies for the treatment of patients with sickle cell disease (SCD). However, Dr Lugthart highlights that developing novel therapeutics is necessary to make this a reality. This interview took place at the 19th Annual Scientific Conference of the Academy for Sickle Cell and Thalassaemia (ASCAT 2024) in London, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Pfizer, Sanius Health, Vertex.
